Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Unresectable or Metastatic Hepatocellular Carcinoma
NCT00006010Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2001
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of docetaxel, gemcitabine in hepatocellular carcinoma (HCC), sponsored by Cancer and Leukemia Group B. Started Sep 2001; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00006010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006010.